SETD2 and leukemia: Interestingly, only two patients had clinically significant somatic mutations, both of which were in SETD2, a methyltransferase commonly altered in leukemias, typically associated with poor prognosis and which may confer chemoresistance (Table 2; Skucha et al. 2019).